NEW YORK (GenomeWeb News) – Gentris and the Shanghai Institutes of Preventative Medicine have signed a memorandum of understanding to collaborate on personalized medicine initiatives.

Under the terms of the deal announced today, the partners will launch research projects to discover, develop, and validate new genomic biomarkers. The goal of the partnership is to create translational research and epidemiological projects and training and education programs focused on pharmacogenomics and clinical sample banking.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.